English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Zendy Open

Presents the pdf analysis as premium feature

PDF Analysis

Insights

Presents the summarisation as premium feature

Summarisation

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the zaia usage as premium feature

ZAIA

Zendy Tools

Zendy Plus

Presents the access of premium content as premium feature

Premium Content

Background  This multicenter study was performed to develop a prognosis‐prediction model incorporating genetic polymorphism with pathologic stage for surgically treated non‐small cell lung cancer ( NSCLC ) patients.    Methods  A replication study including 720 patients and a panel of eight single nucleotide polymorphisms ( SNP s), which predicted the prognosis of surgically treated  NSCLC  in our previous study, was conducted. Using the combined cohort of current and previous studies including 1534 patients, a nomogram for predicting overall survival was made using  C ox proportional hazards regression.    Results  Among the eight  SNP s,  C3  rs2287845,  GNB2L1  (alias  RACK1 ), and rs3756585 were significantly associated with overall survival. A nomogram was constructed based on pathologic stage and the genotypes of the two  SNP s, and the risk score was calculated for each patient in the combined cohort. Using the prognosis‐prediction model, we categorized patients into low, intermediate, and high‐risk groups, which had greater accuracy in predictive ability (log‐rank statistics = 54.66) than the conventional tumor node metastasis staging (log‐rank statistics = 39.56). Next, we generated a prognosis‐prediction model for stage  I  to identify a subgroup of potential candidates for adjuvant chemotherapy. Notably, 97 out of 499 stage  IB  patients were classified as high‐risk patients with a similar prognosis to stage  II  patients, suggesting the benefit of adjuvant chemotherapy.    Conclusions  This prognosis‐prediction model incorporating genetic polymorphism with pathologic stage may lead to more precise prognostication in surgically resected  NSCLC  patients. In particular, this model may be useful in selecting a subgroup of stage  IB  patients who may benefit from adjuvant chemotherapy.

thoracic cancer

Development of a prognosis‐prediction model incorporating genetic polymorphism with pathologic stage in stage I non‐small cell lung cancer:  A  multicenter study